Who
Christopher M. Starr
Director
Company insider
Files Form 4 as: Director, Monopar Therapeutics; Chief Executive Officer, Raptor Pharmaceutical; Chief Executive Officer, Highland Clan Creations.
In numbers
- Trades disclosed
- 196
- Buys
- 0
- Sells
- 28
- Bought
- $0
- Sold
- $8.1M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 26 May 2006
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | $428,400 at $0.005 | filing |
| 1 Oct 2026filed 5 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $362K4,631 at $78.09 | filing |
| 1 Oct 2026filed 5 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $234K2,970 at $78.82 | filing |
| 1 Oct 2026filed 5 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K799 at $79.67 | filing |
| 1 Oct 2026filed 5 Oct 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,400 at $0.00 | filing |
| 2 Dec 2025filed 8 Dec 2025 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,924 at $0.00 | filing |
| 14 Jul 2025filed 16 Jul 2025 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —16,800 at $0.00 | filing |
| 14 Jul 2025filed 16 Jul 2025 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code X | $16816,800 at $0.01 | filing |
| 14 Jul 2025filed 16 Jul 2025 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $672K16,800 at $40.00 | filing |
| 4 Mar 2025filed 7 Mar 2025 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,365 at $0.00 | filing |
| 31 Dec 2023filed 3 Jan 2024 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,533 at $0.00 | filing |
| 31 Dec 2023filed 3 Jan 2024 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,533 | filing |
| 30 Sep 2023filed 3 Oct 2023 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,533 at $0.00 | filing |
| 30 Sep 2023filed 3 Oct 2023 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,533 | filing |
| 30 Jun 2023filed 3 Jul 2023 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,534 at $0.00 | filing |
| 30 Jun 2023filed 3 Jul 2023 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,534 | filing |
| 31 Mar 2023filed 4 Apr 2023 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,533 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,533 | filing |
| 1 Feb 2023filed 3 Feb 2023 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,930 at $0.00 | filing |
| 1 Feb 2023filed 3 Feb 2023 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,133 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.